10月21日，百普赛斯涨5.03%，截至发稿，报61.21元/股，成交1.18亿元，换手率1.56%，总市值102.74 亿元。 资料显示，北京百普赛斯生物科技股份有限公司位于北京市大兴区北京经济技术开发区宏达北路8号4幢 4层,5幢4层，成立日期2010年7月22日，上市日期2021年10月18日，公司主营业务涉及提供重组蛋白等 关键生物试剂产品及技术服务。主营业务收入构成为：重组蛋白82.27%，抗体及其他试剂12.88%，技 术服务3.04%，其他(补充)1.80%。 从基金十大重仓股角度 银华医疗健康混合A（018364）基金经理为张萍、王璐。 截至发稿，张萍累计任职时间6年352天，现任基金资产总规模205.78亿元，任职期间最佳基金回报 184.31%， 任职期间最差基金回报-35.38%。 王璐累计任职时间2年292天，现任基金资产总规模23.01亿元，任职期间最佳基金回报18.57%， 任职期 间最差基金回报-8.36%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个 ...

Core Viewpoint - Baipusais Biotechnology Co., Ltd. has shown a significant stock price increase of 5.03%, reaching 61.21 CNY per share, with a total market capitalization of 10.274 billion CNY as of October 21 [1] Company Overview - Baipusais Biotechnology Co., Ltd. was established on July 22, 2010, and went public on October 18, 2021. The company is located in Beijing Economic and Technological Development Zone [1] - The main business involves providing key biological reagent products and technical services, with revenue composition as follows: 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [1] Fund Holdings - According to data, a fund under Bank of China Securities holds a significant position in Baipusais, with 99,000 shares, accounting for 4.48% of the fund's net value, making it the seventh-largest holding [2] - The fund, named Bank of China Securities Health Industry Mixed Fund (002938), has a total scale of 158 million CNY and has achieved a year-to-date return of 42.47%, ranking 1188 out of 8162 in its category [2] Fund Manager Information - The fund manager of Bank of China Securities Health Industry Mixed Fund is Li Mingwei, who has been in the position for 2 years and 243 days. The fund's total asset size is 158 million CNY [3] - During Li Mingwei's tenure, the best fund return was -4.25%, and the worst was also -4.25% [3]

Group 1 - The core point of the news is that Beijing Baipusi Biotechnology Co., Ltd. has seen a stock price increase of 5.34%, reaching 59.20 CNY per share, with a total market capitalization of 9.937 billion CNY as of October 20 [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - According to data, a fund under Bank of China Securities holds a significant position in Baipusi, with the Bank of China Health Industry Mixed Fund (002938) owning 99,000 shares, accounting for 4.48% of the fund's net value, making it the seventh-largest holding [2] - The Bank of China Health Industry Mixed Fund was established on September 7, 2016, with a current size of 158 million CNY, achieving a year-to-date return of 42.31% and a one-year return of 34.85% [2]

Group 1 - The core point of the news is that Beijing Baipusais Biotechnology Co., Ltd. has seen a stock price increase of 5.1%, reaching 57.66 CNY per share, with a total market capitalization of 9.678 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - The Hongta Hongtu Fund has a significant holding in Baipusais, with its Hongta Hongtu Medical Selected Stock Fund A (020331) being the largest shareholder, holding 10,000 shares, which constitutes 5.61% of the fund's net value [2] - The fund has seen a year-to-date return of 27.02% and a one-year return of 21.23%, ranking 1770 out of 4220 and 2155 out of 3857 in its category, respectively [2] Group 3 - The fund manager of Hongta Hongtu Medical Selected Stock Fund A is Cao Yang, who has been in the position for 2 years and 34 days, with the fund's total asset size at 12.7543 million CNY [3] - During his tenure, the best fund return was 27.6%, while the worst was -33.52% [3]

10月13日，百普赛斯跌5.21%，截至发稿，报58.20元/股，成交1.38亿元，换手率1.82%，总市值97.69亿 元。 资料显示，北京百普赛斯生物科技股份有限公司位于北京市大兴区北京经济技术开发区宏达北路8号4幢 4层,5幢4层，成立日期2010年7月22日，上市日期2021年10月18日，公司主营业务涉及提供重组蛋白等 关键生物试剂产品及技术服务。主营业务收入构成为：重组蛋白82.27%，抗体及其他试剂12.88%，技 术服务3.04%，其他(补充)1.80%。 中银证券健康产业混合（002938）成立日期2016年9月7日，最新规模1.58亿。今年以来收益46.82%，同 类排名1342/8234；近一年收益30.87%，同类排名2755/8083；成立以来收益146.62%。 中银证券健康产业混合（002938）基金经理为李明蔚。 截至发稿，李明蔚累计任职时间2年235天，现任基金资产总规模1.58亿元，任职期间最佳基金回 报-1.21%， 任职期间最差基金回报-1.21%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、 ...

Core Viewpoint - Beijing Baipusi Biotechnology Co., Ltd. has shown a significant stock price increase of 5.07%, reaching 62.58 CNY per share, with a total market capitalization of 10.504 billion CNY as of October 9 [1] Company Overview - Baipusi was established on July 22, 2010, and went public on October 18, 2021. The company is located in Beijing Economic and Technological Development Zone [1] - The main business involves providing key biological reagent products and technical services, with revenue composition as follows: 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [1] Fund Holdings - Tianhong Fund has a significant holding in Baipusi, with Tianhong Healthcare A (001558) owning 414,200 shares, representing 5.9% of the fund's net value, making it the seventh-largest holding [2] - The fund has realized a floating profit of approximately 1.251 million CNY from this investment [2] Fund Performance - Tianhong Healthcare A was established on June 30, 2015, with a current size of 251 million CNY. The fund has achieved a year-to-date return of 44.49%, ranking 1774 out of 8238 in its category [2] - Over the past year, the fund has returned 34.83%, ranking 2489 out of 8082, and since inception, it has delivered a return of 81.87% [2]

10月9日，百普赛斯涨5.07%，截至发稿，报62.58元/股，成交1.05亿元，换手率1.36%，总市值105.04亿 元。 中银证券健康产业混合（002938）基金经理为李明蔚。 截至发稿，李明蔚累计任职时间2年231天，现任基金资产总规模1.58亿元，任职期间最佳基金回报 4.39%， 任职期间最差基金回报4.39%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，北京百普赛斯生物科技股份有限公司位于北京市大兴区北京经济技术开发区宏达北路8号4幢 4层,5幢4层，成立日期2010年7月22日，上市日期2021年10月18日，公司主营业务涉及提供重组蛋白等 关键生物试剂产品及技术服务。主营业务收入构成为：重组蛋白82.27%，抗体及其他试剂12.88%，技 术服务3.04%，其他(补充)1.80%。 从基金十大重仓股角度 数据显示，中银证券旗下1只基金重仓百普赛斯。中银证券健康产业混合（002938）二季度持有股数9.9 万股，占基金净 ...

Group 1 - The stock price of Beijing Baipusi Biotechnology Co., Ltd. dropped by 5.15% to 57.67 CNY per share, with a total market capitalization of 9.68 billion CNY as of the report date [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - The fund "Lubo Mai China Medical Health Stock Initiation A" holds 15,700 shares of Baipusi, accounting for 3.84% of the fund's net value, making it the ninth largest holding [2] - The fund was established on December 26, 2023, with a current scale of 14.52 million CNY, achieving a year-to-date return of 44.16% and a one-year return of 58.26% [2] Group 3 - The fund manager of "Lubo Mai China Medical Health Stock Initiation A" is Li Tao, who has been in the position for 1 year and 261 days, with total assets under management of 29.25 million CNY [3] - During Li Tao's tenure, the best fund return was 17%, while the worst was 15.79% [3]

Group 1 - The core point of the news is the decline in the stock price of Beijing Baipusi Biotechnology Co., Ltd., which fell by 5.13% to 57.30 CNY per share, with a total market capitalization of 9.618 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] - The trading volume for the stock was 113 million CNY, with a turnover rate of 1.53% [1] Group 2 - According to data, a fund under Bank of China Securities holds a significant position in Baipusi, with the Bank of China Health Industry Mixed Fund (002938) owning 99,000 shares, accounting for 4.48% of the fund's net value, making it the seventh-largest holding [2] - The fund has a total scale of 158 million CNY and has achieved a year-to-date return of 63.37%, ranking 206 out of 8178 in its category [2] - The fund manager, Li Mingwei, has been in charge for 2 years and 197 days, with the best and worst fund returns during his tenure both being 9.92% [3]

Group 1 - The core point of the news is that Beijing Baipusi Biotechnology Co., Ltd. experienced a stock decline of 5.21%, with a current share price of 53.35 yuan and a total market capitalization of 8.955 billion yuan [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing recombinant proteins and key biological reagent products and technical services [1] - The revenue composition of the company includes 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other supplementary sources [1] Group 2 - From the perspective of major fund holdings, Guotai Fund has a significant position in Baipusi, with its Guotai Quantitative Income Flexible Allocation Mixed A fund holding 7,700 shares, accounting for 1.25% of the fund's net value [2] - The fund has reported a year-to-date return of 27.05% and a one-year return of 58.29%, ranking 2282 out of 8191 and 1731 out of 7967 respectively in its category [2] - The fund manager, Liang Xing, has a tenure of 9 years and 84 days, with the fund's total asset scale at 24.955 billion yuan, achieving a best return of 189.2% during his tenure [2]